Pfizer to Seek Emergency Approval for COVID-19 Vaccine

Pfizer is moving ahead with the request of asking the US regulators to allow emergency use of its coronavirus vaccine.

Pfizer is moving ahead with the request of asking the US regulators to allow emergency use of its coronavirus vaccine. In the last 10 days the vaccine has shown 95 per cent efficacy in a totality of two data sets.

Unless some nasty surprises turn up, Pfizer's action on Friday could be the first step towards vaccinating the most vulnerable Americans by December end.

Pfizer 2-Dose COVID-19 Vaccine 95% Effective
The second batch of interim results released by Pfizer revealed that the two-dose coronavirus vaccine candidate is 95% effective.

‘Pfizer and BioNTech expect to produce a total of 50 million COVID-19 vaccine doses in 2020 and up to 1.3 billion doses in 2021. US regulators hope to have 20 million vaccine doses each from Moderna and Pfizer available for distribution in late December.’

Pfizer and another US company, Moderna, have broken all vaccine development speed records in their race for a cure over the last nine months.

US regulators are standing by for the approval process while coronavirus cases are surging to record levels across all the 50 states.

The Vaccines and Related Biological Products Advisory Committee in the US Food and Drug Administration is a key player in how this process rolls along.

COVID-19 Vaccine: 20 Million Americans Could Get the Vaccine in Dec 2020
In December, roughly 20 million people could be vaccinated against the coronavirus, the chief of the Donald Trump administration's vaccine coordination program said today.

Pfizer's submission also includes safety data on approximately 100 children aged 12-15 years.

"Our work to deliver a safe and effective vaccine has never been more urgent," Pfizer CEO Albert Bourla said in a statement.

AstraZeneca COVID-19 Vaccine to be Ready by Dec
The Serum Institute of India (SII) aims to have 100 million doses of AstraZeneca's coronavirus vaccine for a vaccination drive.

Source-IANS

Face Mask � a Transitory Substitute to COVID-19 Vaccine?
Universal facial masking may show an effective possibility for inducing variolation against the SARS-CoV-2 virus until we anticipate the COVID-19 vaccine.